![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication August 18, 2005.
Revised September 25, 2005.
Accepted for publication October 4, 2005.
6 Nicotinic acetylcholine receptors; potential targets for Parkinson's disease therapy
The presence of distinct nicotinic acetylcholine receptor (nAChR) subtypes in specific CNS areas offers the possibility of developing targeted therapies for diseases involving the affected brain region. Parkinson's disease is a neurodegenerative movement disorder characterized by a progressive degeneration of the nigrostriatal system. 
6-containing nAChRs (designated 6* nAChRs) have a relatively selective localization to the nigrostriatal pathway and a limited number of other CNS regions. In addition to a unique distribution, this subtype has a distinct pharmacology and specifically interacts with -conotoxinMII, a toxin key in its identification and characterization. 6* nAChRs are also regulated in a novel manner with a decrease in their number after nicotine treatment, rather than the increase observed for 4* nAChRs. Striatal 6* receptors are functional and mediate dopamine release suggesting they have a presynaptic localization. This is further supported by lesion studies showing that both 6* nAChR sites and their function are dramatically decreased with dopaminergic nerve terminal loss, in contrast to only small declines in 4* and no change in 7* receptors. Although the role of nigrostriatal 6* nAChRs is only beginning to be understood, an involvement in motor behavior is emerging. This latter observation coupled with the finding that nicotine protects against nigrostriatal damage suggest that 6* nAChRs may represent unique targets for neurodegenerative disorders linked to the nigrostriatal system such as Parkinson's disease.
Key words:
Parkinson's disease, alpha-conotoxinMII, alpha6, nicotine, nicotinic, striatum
This article has been cited by other articles:
|
|
 |
|
  X. A. Perez, T. Bordia, J. M. McIntosh, S. R. Grady, and M. Quik Long-Term Nicotine Treatment Differentially Regulates Striatal {alpha}6{alpha}4{beta}2* and {alpha}6(Non{alpha}4){beta}2* nAChR Expression and Function Mol. Pharmacol., September 1, 2008; 74(3): 844 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. O'Leary, N. Parameswaran, J. M. McIntosh, and M. Quik Cotinine Selectively Activates a Subpopulation of {alpha}3/{alpha}6{beta}2 Nicotinic Receptors in Monkey Striatum J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 646 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Azam, D. Yoshikami, and J. M. McIntosh Amino Acid Residues That Confer High Selectivity of the {alpha}6 Nicotinic Acetylcholine Receptor Subunit to {alpha}-Conotoxin MII[S4A,E11A,L15A] J. Biol. Chem., April 25, 2008; 283(17): 11625 - 11632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Walsh, A. P. Govind, R. Mastro, J. C. Hoda, D. Bertrand, Y. Vallejo, and W. N. Green Up-regulation of Nicotinic Receptors by Nicotine Varies with Receptor Subtype J. Biol. Chem., March 7, 2008; 283(10): 6022 - 6032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Zeiger, B. C. Haberstick, I. Schlaepfer, A. C. Collins, R. P. Corley, T. J. Crowley, J. K. Hewitt, C. J. Hopfer, J. Lessem, M. B. McQueen, et al. The neuronal nicotinic receptor subunit genes (CHRNA6 and CHRNB3) are associated with subjective responses to tobacco Hum. Mol. Genet., March 1, 2008; 17(5): 724 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Drenan, R. Nashmi, P. Imoukhuede, H. Just, S. McKinney, and H. A. Lester Subcellular Trafficking, Pentameric Assembly, and Subunit Stoichiometry of Neuronal Nicotinic Acetylcholine Receptors Containing Fluorescently Labeled {alpha}6 and 3 Subunits Mol. Pharmacol., January 1, 2008; 73(1): 27 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zanardi, R. Ferrari, G. Leo, U. Maskos, J.-P. Changeux, and M. Zoli Loss of high-affinity nicotinic receptors increases the vulnerability to excitotoxic lesion and decreases the positive effects of an enriched environment FASEB J, December 1, 2007; 21(14): 4028 - 4037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bordia, S. R. Grady, J. M. McIntosh, and M. Quik Nigrostriatal Damage Preferentially Decreases a Subpopulation of {alpha}6beta2* nAChRs in Mouse, Monkey, and Parkinson's Disease Striatum Mol. Pharmacol., July 1, 2007; 72(1): 52 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bordia, N. Parameswaran, H. Fan, J. W. Langston, J. M. McIntosh, and M. Quik Partial Recovery of Striatal Nicotinic Receptors in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Monkeys with Chronic Oral Nicotine J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 285 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tumkosit, A. Kuryatov, J. Luo, and J. Lindstrom beta3 Subunits Promote Expression and Nicotine-Induced Up-Regulation of Human Nicotinic {alpha}6* Nicotinic Acetylcholine Receptors Expressed in Transfected Cell Lines Mol. Pharmacol., October 1, 2006; 70(4): 1358 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. McCallum, N. Parameswaran, T. Bordia, H. Fan, J. M. McIntosh, and M. Quik Differential Regulation of Mesolimbic {alpha}3/{alpha}6beta2 and {alpha}4beta2 Nicotinic Acetylcholine Receptor Sites and Function after Long-Term Oral Nicotine to Monkeys J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 381 - 388. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
